Rationale and design of the Tanzania Vitamin and HIV Infection Trial.
about
Human papillomavirus-16 modifies the association between fruit consumption and head and neck squamous cell carcinomaVitamin A supplementation during pregnancy for maternal and newborn outcomesMicronutrient supplementation in pregnant women with HIV infectionVitamin A supplementation for reducing the risk of mother-to-child transmission of HIV infectionTreatment for anemia in people with AIDSVitamin A supplementation during pregnancy for maternal and newborn outcomesInterventions for preventing late postnatal mother-to-child transmission of HIVVitamin A supplementation for reducing the risk of mother-to-child transmission of HIV infectionVitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality.Early phase clinical trials with human immunodeficiency virus-1 and malaria vectored vaccines in The Gambia: frontline challenges in study design and implementation.Malaria parasitemia and CD4 T cell count, viral load, and adverse HIV outcomes among HIV-infected pregnant women in TanzaniaSupplementation with multivitamins and vitamin A and incidence of malaria among HIV-infected Tanzanian women.Lipid-soluble vitamins A, D, and E in HIV-infected pregnant women in TanzaniaVitamin D status and its association with morbidity including wasting and opportunistic illnesses in HIV-infected women in Tanzania.Post-natal anaemia and iron deficiency in HIV-infected women and the health and survival of their children.Predictors of anaemia and iron deficiency in HIV-infected pregnant women in Tanzania: a potential role for vitamin D and parasitic infectionsRelationship of exclusive breast-feeding to infections and growth of Tanzanian children born to HIV-infected women.The Nigerian antihypertensive adherence trial: a community-based randomized trial.Maternal vitamin D status and child morbidity, anemia, and growth in human immunodeficiency virus-exposed children in TanzaniaTime-independent maternal and infant factors and time-dependent infant morbidities including HIV infection, contribute to infant growth faltering during the first 2 years of life.Perinatal outcomes, including mother-to-child transmission of HIV, and child mortality and their association with maternal vitamin D status in TanzaniaPatterns and predictors of CD4 T-cell counts among children born to HIV-infected women in Tanzania.C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting.Vitamin A supplements for reducing mother-to-child HIV transmission.Selenium levels in relation to morbidity and mortality among children born to HIV-infected mothers.Prevalence and risk factors for skin diseases among antiretroviral-naïve HIV-infected pregnant women in Dar es Salaam, Tanzania.Association of maternal depression and infant nutritional status among women living with HIV in Tanzania.Multivitamin supplementation in HIV-positive pregnant women: impact on depression and quality of life in a resource-poor setting.Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype.Validity of the Hopkins Symptom Checklist-25 amongst HIV-positive pregnant women in Tanzania.
P2860
Q23917546-2864B478-3581-4743-9ADD-AAE75EE3BF84Q24186343-1210A0D0-8395-4E20-B17E-60B300EB745EQ24201137-AD9DCF16-E6CE-4B06-9006-FF91FB4A1647Q24234927-398A9C48-1DB5-48DE-9B73-2931D16C6362Q24235994-220FCE54-6AB1-41C8-8A04-BA049B8C9369Q24236618-2CA8A6E1-AD4B-422D-95A3-314E8D13B6E6Q24241793-4DC09F92-2160-4814-AA78-156A145EC779Q24245896-A73B145F-87AD-4B2F-B00B-AC9A332859BFQ33526366-40D3ED81-0A79-4C9F-8537-8F5DFBEBBDF9Q33588543-3CA9E28E-A3EB-4B7B-A290-C719CCB02BB5Q33749682-1E7C39EA-18D1-48F1-915C-A0089CEA68EBQ34611339-59C5AAB3-DF80-4027-96DA-DA7036705515Q34808052-4E408AAB-1824-4BA3-B036-6EDA653B9793Q35245597-2827A951-58AE-4394-A8CB-E4423916E766Q35899189-B8172677-FEF9-4CE5-8DC4-30DDD11D813DQ36004844-0225E215-0BCA-40E0-BEB9-988FFDF88333Q36004855-5A531CC9-E3F6-4153-8FB9-930DE8FBCDF9Q36489758-56FAC02A-CA92-414B-9F04-1D18468D34BCQ37268999-25080333-5114-47DE-B132-AB9AA583E21AQ37324765-2089C0CE-AAB3-4E52-B54E-A510D08E05B4Q37379462-FD026205-D746-4222-AD38-371A3459B7A4Q37398582-F874C6B2-BE3F-4DE6-961F-F34232F0DEFBQ37734639-80C8DE26-72C1-4A1E-85FF-E53AA9740D17Q40053700-94095ED5-F90E-4560-A93B-846E6AEC6966Q40405666-A7ADF3AD-382E-48B0-BFAD-AAB486BB1D21Q42203322-F3401422-E6CE-4718-A168-C4B0F22F0BA9Q43933788-F1E75793-B8A7-4AC1-AF30-1EC936A301DEQ43945886-01A283DF-09D0-4A54-8ADF-CCC35D57B223Q43947197-42D26B03-39BD-404C-9FDE-D8A893CE925AQ43950293-D2DD55C8-8164-457B-BCEA-959FCB707753
P2860
Rationale and design of the Tanzania Vitamin and HIV Infection Trial.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Rationale and design of the Tanzania Vitamin and HIV Infection Trial.
@en
Rationale and design of the Tanzania Vitamin and HIV Infection Trial.
@nl
type
label
Rationale and design of the Tanzania Vitamin and HIV Infection Trial.
@en
Rationale and design of the Tanzania Vitamin and HIV Infection Trial.
@nl
prefLabel
Rationale and design of the Tanzania Vitamin and HIV Infection Trial.
@en
Rationale and design of the Tanzania Vitamin and HIV Infection Trial.
@nl
P2093
P1476
Rationale and design of the Tanzania Vitamin and HIV Infection Trial.
@en
P2093
Msamanga GI
Spiegelman D
P356
10.1016/S0197-2456(98)00045-2
P407
P577
1999-02-01T00:00:00Z